Liquid Biopsy in Type 2 Diabetes Mellitus Management: Building Specific Biosignatures via Machine Learning

Background: The need for minimally invasive biomarkers for the early diagnosis of type 2 diabetes (T2DM) prior to the clinical onset and monitoring of β-pancreatic cell loss is emerging. Here, we focused on studying circulating cell-free DNA (ccfDNA) as a liquid biopsy biomaterial for accurate diagn...

Descripción completa

Detalles Bibliográficos
Autores principales: Karaglani, Makrina, Panagopoulou, Maria, Cheimonidi, Christina, Tsamardinos, Ioannis, Maltezos, Efstratios, Papanas, Nikolaos, Papazoglou, Dimitrios, Mastorakos, George, Chatzaki, Ekaterini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876363/
https://www.ncbi.nlm.nih.gov/pubmed/35207316
http://dx.doi.org/10.3390/jcm11041045

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876363/
https://www.ncbi.nlm.nih.gov/pubmed/35207316
http://dx.doi.org/10.3390/jcm11041045

Ejemplares similares